Pharma Focus Asia
KP - Choose our fully recyclable blister films

AstraZeneca and Daiichi Sankyo Recommend for Approval of Enhertu

Saturday, September 16, 2023

Enhertu, developed jointly by AstraZeneca and Daiichi Sankyo, has received a recommendation for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). 

This recommendation applies to patients whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

Enhertu is a specifically engineered antibody-drug conjugate (ADC) directed at HER2. It comprises a HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload, which is an exatecan derivative. This linkage is achieved through a stable tetrapeptide-based cleavable linker.

In the clinical trial, Enhertu administered at a dose of 5.4mg/kg exhibited a confirmed objective response rate (ORR) of 49.0 percent (with a 95 percent confidence interval [CI] ranging from 39.0 to 59.1 percent) and a disease control rate (DCR) of 93.1 percent in patients who had previously received treatment for advanced or metastatic HER2-mutant (HER2m) non-small cell lung cancer (NSCLC).

Previously, Enhertu had received approval in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. These patients had received one or more prior anti-HER2-based regimens, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and had developed disease recurrence during or within six months of completing therapy.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024